{"id":"https://openalex.org/W2155086643","doi":"https://doi.org/10.1124/dmd.112.049585","title":"Nanoparticle Formulation of a Poorly Soluble Cannabinoid Receptor 1 Antagonist Improves Absorption by Rat and Human Intestine","display_name":"Nanoparticle Formulation of a Poorly Soluble Cannabinoid Receptor 1 Antagonist Improves Absorption by Rat and Human Intestine","publication_year":2013,"publication_date":"2013-06-04","ids":{"openalex":"https://openalex.org/W2155086643","doi":"https://doi.org/10.1124/dmd.112.049585","mag":"2155086643","pmid":"https://pubmed.ncbi.nlm.nih.gov/23733277"},"language":"en","primary_location":{"id":"doi:10.1124/dmd.112.049585","doi":"https://doi.org/10.1124/dmd.112.049585","is_oa":false,"landing_page_url":"https://doi.org/10.1124/dmd.112.049585","pdf_url":null,"source":{"id":"https://openalex.org/S145039780","display_name":"Drug Metabolism and Disposition","issn_l":"0090-9556","issn":["0090-9556","1521-009X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Metabolism and Disposition","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://research.rug.nl/en/publications/da4218c9-aa8b-4902-a163-c9db22fdfa54","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082259853","display_name":"Sanna Siissalo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Sanna Siissalo","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting, University of Groningen, Groningen, the Netherlands","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017321417","display_name":"Hans de Waard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Hans de Waard","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079721714","display_name":"Marina H. de Jager","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Marina H. de Jager","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048581384","display_name":"Rose K. Hayeshi","orcid":"https://orcid.org/0000-0002-1836-2179","observed_orcids":["https://orcid.org/0000-0002-1836-2179"]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Rose Hayeshi","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008287871","display_name":"Henderik Willem Frijlink","orcid":"https://orcid.org/0000-0001-7901-8198","observed_orcids":["https://orcid.org/0000-0001-7901-8198"]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Henderik W. Frijlink","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013977907","display_name":"Wouter L.J. Hinrichs","orcid":"https://orcid.org/0000-0002-1481-2769","observed_orcids":["https://orcid.org/0000-0002-1481-2769"]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Wouter L.J. Hinrichs","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026258992","display_name":"Heike Dinter-Heidorn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Heike Dinter-Heidorn","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047763098","display_name":"Annie van Dam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Annie van Dam","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057349563","display_name":"Johannes H. Proost","orcid":"https://orcid.org/0000-0002-7155-783X","observed_orcids":["https://orcid.org/0000-0002-7155-783X"]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Johannes H. Proost","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062954228","display_name":"Geny M. M. Groothuis","orcid":"https://orcid.org/0000-0002-6501-0512","observed_orcids":["https://orcid.org/0000-0002-6501-0512"]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Geny M.M. Groothuis","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001597354","display_name":"Inge A.M. de Graaf","orcid":"https://orcid.org/0000-0002-0760-8356","observed_orcids":["https://orcid.org/0000-0002-0760-8356"]},"institutions":[{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]},{"id":"https://openalex.org/I4210126753","display_name":"Abbott (Germany)","ror":"https://ror.org/02x2gk324","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210088555","https://openalex.org/I4210126753"]}],"countries":["DE","NL"],"is_corresponding":false,"raw_author_name":"Inge A.M. de Graaf","raw_affiliation_strings":["Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","Abbott Products GmbH, Hannover, Germany (H.D-H.)","Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands; Abbott Products GmbH, Hannover, Germany (H.D-H.); Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Abbott Products GmbH, Hannover, Germany (H.D-H.)","institution_ids":["https://openalex.org/I4210126753"]},{"raw_affiliation_string":"Division of Pharmacokinetics, Toxicology, and Targeting (S.S., M.H.J., R.H., J.H.P., G.M.M.G., I.A.M.G.), and Division of Pharmaceutical Technology and Biopharmacy (H.W., H.W.F., W.L.J.H.), Department of Pharmacy, University of Groningen, Groningen, the Netherlands","institution_ids":["https://openalex.org/I169381384"]},{"raw_affiliation_string":"Mass Spectrometry Core Facility, University of Groningen, Groningen, the Netherlands (A.D.)","institution_ids":["https://openalex.org/I169381384"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3500,"currency":"USD","value_usd":3500},"apc_paid":null,"fwci":0.8026,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.72422758,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"41","issue":"8","first_page":"1557","last_page":"1565"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nanoparticle-formulation","display_name":"nanoparticle formulation","score":0.7390000224113464},{"id":"https://openalex.org/keywords/solid-dispersion","display_name":"solid dispersion","score":0.7319999933242798},{"id":"https://openalex.org/keywords/poorly-water-soluble-drugs","display_name":"poorly water-soluble drugs","score":0.8370000123977661},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.9520000219345093},{"id":"https://openalex.org/keywords/intestinal-absorption","display_name":"intestinal absorption","score":0.8289999961853027},{"id":"https://openalex.org/keywords/dissolution-rate","display_name":"dissolution rate","score":0.6919999718666077},{"id":"https://openalex.org/keywords/ussing-chamber","display_name":"Ussing chamber","score":0.7329999804496765},{"id":"https://openalex.org/keywords/metabolite-formation","display_name":"metabolite production","score":0.7160000205039978},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.828000009059906},{"id":"https://openalex.org/keywords/drug-delivery-to-the-brain","display_name":"brain drug delivery","score":0.7179999947547913},{"id":"https://openalex.org/keywords/bcs-class-ii-drugs","display_name":"BCS class II drugs","score":0.7170000076293945}],"concepts":[{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.9047025442123413},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6660385131835938},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.6543722748756409},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6411305665969849},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5770604014396667},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.5680669546127319},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5570496320724487},{"id":"https://openalex.org/C2779783865","wikidata":"https://www.wikidata.org/wiki/Q410228","display_name":"Anandamide","level":5,"score":0.4979426860809326},{"id":"https://openalex.org/C125287762","wikidata":"https://www.wikidata.org/wiki/Q1758948","display_name":"Absorption (acoustics)","level":2,"score":0.48378631472587585},{"id":"https://openalex.org/C2781430271","wikidata":"https://www.wikidata.org/wiki/Q278760","display_name":"Biopharmaceutics Classification System","level":3,"score":0.4542369246482849},{"id":"https://openalex.org/C148001335","wikidata":"https://www.wikidata.org/wiki/Q421237","display_name":"Cannabinoid receptor","level":4,"score":0.3886769413948059},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.38614004850387573},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.36968570947647095},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2605360746383667},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.24065643548965454},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.18620210886001587},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.1788330376148224},{"id":"https://openalex.org/C159985019","wikidata":"https://www.wikidata.org/wiki/Q181790","display_name":"Composite material","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001921","descriptor_name":"Brain","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007408","descriptor_name":"Intestinal Absorption","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012995","descriptor_name":"Solubility","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017208","descriptor_name":"Rats, Wistar","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D043884","descriptor_name":"Receptor, Cannabinoid, CB1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053758","descriptor_name":"Nanoparticles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D063387","descriptor_name":"Cannabinoid Receptor Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D063387","descriptor_name":"Cannabinoid Receptor Antagonists","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D063387","descriptor_name":"Cannabinoid Receptor Antagonists","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1124/dmd.112.049585","doi":"https://doi.org/10.1124/dmd.112.049585","is_oa":false,"landing_page_url":"https://doi.org/10.1124/dmd.112.049585","pdf_url":null,"source":{"id":"https://openalex.org/S145039780","display_name":"Drug Metabolism and Disposition","issn_l":"0090-9556","issn":["0090-9556","1521-009X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Metabolism and Disposition","raw_type":"journal-article"},{"id":"pmid:23733277","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23733277","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug metabolism and disposition: the biological fate of chemicals","raw_type":"Journal Article"},{"id":"pmh:oai:pure.rug.nl:openaire/da4218c9-aa8b-4902-a163-c9db22fdfa54","doi":null,"is_oa":true,"landing_page_url":"https://research.rug.nl/en/publications/da4218c9-aa8b-4902-a163-c9db22fdfa54","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Siissalo, S, De Waard, H, De Jager, M H, Hayeshi, R, Frijlink, H W, Hinrichs, W L J, Dinter-Heidorn, H, Van Dam, A, Proost, J H, Groothuis, G M M & De Graaf, I A M 2013, 'Nanoparticle formulation of a poorly soluble cannabinoid receptor 1 antagonist improves absorption by rat and human intestine', Drug Metabolism and Disposition, vol. 41, no. 8, pp. 1557-1565. https://doi.org/10.1124/dmd.112.049585","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:rug:oai:pure.rug.nl:publications/da4218c9-aa8b-4902-a163-c9db22fdfa54","doi":null,"is_oa":false,"landing_page_url":"https://research.rug.nl/en/publications/da4218c9-aa8b-4902-a163-c9db22fdfa54","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Drug Metabolism and Disposition, 41(8), 1557 - 1565. AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:pure.rug.nl:openaire/da4218c9-aa8b-4902-a163-c9db22fdfa54","doi":null,"is_oa":true,"landing_page_url":"https://research.rug.nl/en/publications/da4218c9-aa8b-4902-a163-c9db22fdfa54","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Siissalo, S, De Waard, H, De Jager, M H, Hayeshi, R, Frijlink, H W, Hinrichs, W L J, Dinter-Heidorn, H, Van Dam, A, Proost, J H, Groothuis, G M M & De Graaf, I A M 2013, 'Nanoparticle formulation of a poorly soluble cannabinoid receptor 1 antagonist improves absorption by rat and human intestine', Drug Metabolism and Disposition, vol. 41, no. 8, pp. 1557-1565. https://doi.org/10.1124/dmd.112.049585","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W192454658","https://openalex.org/W1498305210","https://openalex.org/W1561800528","https://openalex.org/W1964085724","https://openalex.org/W1973960007","https://openalex.org/W1976451953","https://openalex.org/W1979086975","https://openalex.org/W1980792687","https://openalex.org/W2011707100","https://openalex.org/W2011920500","https://openalex.org/W2030136078","https://openalex.org/W2030951340","https://openalex.org/W2034163151","https://openalex.org/W2069105661","https://openalex.org/W2072922667","https://openalex.org/W2078775644","https://openalex.org/W2135732933","https://openalex.org/W2145559671","https://openalex.org/W2151857779","https://openalex.org/W2155942988","https://openalex.org/W2156321359","https://openalex.org/W2169552920","https://openalex.org/W2589050468","https://openalex.org/W2951916227"],"related_works":["https://openalex.org/W2069909271","https://openalex.org/W4283219805","https://openalex.org/W2003700884","https://openalex.org/W4311290483","https://openalex.org/W2039000434","https://openalex.org/W3097308143","https://openalex.org/W4415765370","https://openalex.org/W4381469762","https://openalex.org/W2895658037","https://openalex.org/W2512746604"],"abstract_inverted_index":null,"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}